Philip Bejon
Philip Bejon
KEMRI-Wellcome
Verified email at kemri-wellcome.org
Title
Cited by
Cited by
Year
First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children
RTS, S Clinical Trials Partnership
New England Journal of Medicine 365 (20), 1863-1875, 2011
7752011
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya
WP O'Meara, P Bejon, TW Mwangi, EA Okiro, N Peshu, RW Snow, ...
The lancet 372 (9649), 1555-1562, 2008
4962008
Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age
P Bejon, J Lusingu, A Olotu, A Leach, M Lievens, J Vekemans, S Mshamu, ...
New England Journal of Medicine 359 (24), 2521-2532, 2008
4742008
Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised …
S Rts
The Lancet 386 (9988), 31-45, 2015
4482015
Upregulation of TGF-β, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection
M Walther, JE Tongren, L Andrews, D Korbel, E King, H Fletcher, ...
Immunity 23 (3), 287-296, 2005
4262005
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ...
New England Journal of Medicine 374 (17), 1647-1660, 2016
3582016
One hundred and twelve infected arthroplasties treated with ‘DAIR’(debridement, antibiotics and implant retention): antibiotic duration and outcome
I Byren, P Bejon, BL Atkins, B Angus, S Masters, P McLardy-Smith, ...
Journal of antimicrobial chemotherapy 63 (6), 1264-1271, 2009
3062009
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
DP Webster, S Dunachie, JM Vuola, T Berthoud, S Keating, SM Laidlaw, ...
Proceedings of the National Academy of Sciences 102 (13), 4836-4841, 2005
3062005
A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants.
S Rts, ST Agnandji, B Lell, JF Fernandes, BP Abossolo, BG Methogo, ...
The New England journal of medicine 367 (24), 2284-95, 2012
273*2012
Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure
A Olotu, G Fegan, J Wambua, G Nyangweso, KO Awuondo, A Leach, ...
New England Journal of Medicine 368 (12), 1111-1120, 2013
2722013
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya
P Bejon, TN Williams, A Liljander, AM Noor, J Wambua, E Ogada, A Olotu, ...
PLoS Med 7 (7), e1000304, 2010
2502010
Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children
A Olotu, G Fegan, J Wambua, G Nyangweso, A Leach, M Lievens, ...
New England Journal of Medicine 374 (26), 2519-2529, 2016
2372016
Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine
DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ...
New England Journal of Medicine 373 (21), 2025-2037, 2015
2332015
Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion
J Illingworth, NS Butler, S Roetynck, J Mwacharo, SK Pierce, P Bejon, ...
The Journal of Immunology 190 (3), 1038-1047, 2013
2062013
Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a …
A Olotu, J Lusingu, A Leach, M Lievens, J Vekemans, S Msham, T Lang, ...
The Lancet infectious diseases 11 (2), 102-109, 2011
1792011
A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria …
SJ Dunachie, M Walther, JE Epstein, S Keating, T Berthoud, L Andrews, ...
Infection and immunity 74 (10), 5933-5942, 2006
1742006
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers …
P Bejon, L Andrews, RF Andersen, S Dunachie, D Webster, M Walther, ...
The Journal of infectious diseases 191 (4), 619-626, 2005
1742005
Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites
RTS, S Clinical Trials Partnership (2014)
PLoS medicine 11 (7), e1001685, 2014
1722014
Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology
P Bejon, A Berendt, BL Atkins, N Green, H Parry, S Masters, ...
Journal of antimicrobial chemotherapy 65 (3), 569-575, 2010
1682010
Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
MT White, R Verity, JT Griffin, KP Asante, S Owusu-Agyei, B Greenwood, ...
The Lancet infectious diseases 15 (12), 1450-1458, 2015
1662015
The system can't perform the operation now. Try again later.
Articles 1–20